Physician profile
Patrick J Sheets
NPI 1396704268
$5,523.80
in general payments reported to CMS, 2019-2025
49 companies · $88.38 in 2025
The $88.38 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $713 · 2020: $838 · 2021: $1,536 · 2022: $1,261 · 2023: $577 · 2024: $511 · 2025: $88.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,176.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,171.10 | 2019-2025 | Linzess, Ubrelvy, Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $547.26 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $292.30 | 2019-2024 | Breztri |
| Janssen Pharmaceuticals, INC | $276.31 | 2019-2022 | |
| Allergan, INC. | $270.42 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $262.47 | 2019-2020 | |
| Electromed, INC. | $216.74 | 2021-2024 | Smartvest |
| Sunovion Pharmaceuticals INC. | $213.05 | 2019-2022 | |
| Lilly USA, LLC | $177.43 | 2021-2023 | Mounjaro |
| Astellas Pharma US INC | $170.54 | 2019-2021 | |
| Mylan Specialty L.P. | $170.48 | 2019-2023 | Yupelri |
| Novo Nordisk INC | $170.44 | 2020-2023 | Rybelsus, Ozempic |
| Pfizer INC. | $138.07 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $125.34 | 2021-2024 | Rexulti, Nuedexta, Abilify Maintena |
| Jazz Pharmaceuticals INC. | $123.93 | 2019-2021 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Sheets listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.